Table 1.
Clinical and serological characteristics of the CE and non-CE cohorts
| Group stage | Number (%) | Indirect hemagglutination, positive (%) | ELISA, positive (%) | Western blot, positive (%) |
|---|---|---|---|---|
| CE cohort | ||||
| Active | 52 (50.0) | 40 (76.9) | 39 (75.0) | 44 (84.6) |
| CE1 | 5 (4.8) | 3 (60.0) | 2 (40.0) | 4 (80.0) |
| CE2 | 10 (9.6) | 7 (70.0) | 7 (70.0) | 9 (90.0) |
| CE3a | 13 (12.5) | 11 (84.6) | 12 (92.3) | 10 (76.9) |
| CE3b | 24 (23.1) | 19 (79.2) | 18 (75.0) | 21 (87.5) |
| Inactive | 52 (50.0) | 10 (19.2) | 10 (19.2) | 16 (30.8) |
| CE4 | 28 (26.9) | 6 (21.4) | 9 (32.1) | 11 (39.3) |
| CE5 | 24 (23.1) | 4 (16.7) | 1 (4.2) | 5 (20.8) |
| Total | 104 (100) | 50 (48.1) | 49 (47.1) | 60 (57.7) |
| Non-CE Cohort | ||||
| Liquid | 245 (95.3) | 2 (0.8) | 2 (0.8) | 0 (0.0) |
| Solid | 12 (4.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Total | 257 (100) | 2 (0.8) | 2 (0.8) | 0 (0.0) |
CE = cystic echinococcosis.